Home / Market News / $SYRE

$SYRE news and market catalysts

The 15 most recent market catalysts affecting $SYRE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 1 high impact 9 bullish 3 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Bullish Impact 55
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $141 From $123, Maintains Buy Rating
Deutsche Bank updated its outlook on Spyre Therapeutics, raising the price target from $123 to $141 and reaffirming a Buy rating. This action signals a continued positive assessmen…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform Rating on Spyre Therapeutics, Lowers Price Target
Wedbush maintained its 'Outperform' rating on Spyre Therapeutics (SYRE), indicating continued positive sentiment towards the company. However, the price target was slightly lowered…
Oct 19, 2026 Corporate Catalyst Bullish Impact 75
Spyre Therapeutics shares are trading higher after BTIG reiterated its Buy rating on the stock and maintained a $121 price target.
This headline represents a significant corporate catalyst for Spyre Therapeutics. A reiterated 'Buy' rating from a reputable firm like BTIG, coupled with a high price target, acts …
Oct 19, 2026 Corporate Catalyst Neutral Impact 55
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
BTIG analyst Julian Harrison reiterated a 'Buy' rating and maintained a $121 price target for Spyre Therapeutics (SYRE). This action signals continued confidence from a prominent a…
Oct 12, 2026 Corporate Catalyst Neutral Impact 65
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120
UBS analyst Alice Nettleton has initiated coverage on Spyre Therapeutics (SYRE) with a 'Buy' rating and a $120 price target. This is a significant event for SYRE as new analyst cov…
Oct 1, 2026 Corporate Catalyst Neutral Impact 65
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110
JP Morgan's initiation of coverage on Spyre Therapeutics with an 'Overweight' rating and a $110 price target is a significant positive development for the company. Analyst coverage…
Aug 26, 2026 Corporate Catalyst Bearish Impact 95
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles
Spyre Therapeutics (SYRE) reported topline results for its SPY072 rheumatoid arthritis (RA) program, indicating that while the drug showed statistical significance in improving sym…
Aug 26, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123
Wedbush analyst David Nierengarten reiterated an 'Outperform' rating for Spyre Therapeutics, signaling continued confidence in the company's long-term prospects. However, the price…
Aug 11, 2026 Corporate Catalyst Bullish Impact 65
BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132
BTIG analyst Julian Harrison has maintained a 'Buy' rating on Spyre Therapeutics (SYRE) and raised the price target from $112 to $132. This action signals increased confidence from…
Aug 5, 2026 Corporate Catalyst Bullish Impact 65
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115
Wells Fargo analyst Yanan Zhu has maintained an 'Overweight' rating on Spyre Therapeutics and raised the price target from $90 to $115. This indicates a stronger conviction from th…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating for Spyre Therapeutics and raised the price target from $115 to $130. This action signals increased confidence from a prom…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
Wedbush analyst David Nierengarten has raised the price target for Spyre Therapeutics (SYRE) from $100 to $130 while maintaining an Outperform rating. This action signals increased…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
Spyre Therapeutics (SYRE) announced Q2 losses of $(0.36) per share, significantly beating the analyst consensus estimate of $(0.73) by over 50%. This also represents a 26.53% impro…
Jul 28, 2026 Corporate Catalyst Bearish Impact 55
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Wolfe Research, through analyst Andy Chen, has downgraded Spyre Therapeutics (SYRE) from an 'Outperform' rating to 'Peer Perform'. This matters because analyst ratings can influenc…
Jul 13, 2026 Corporate Catalyst Bullish Impact 65
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120
Mizuho analyst Joseph Catanzaro has raised the price target for Spyre Therapeutics (SYRE) from $84 to $120, while maintaining an Outperform rating. This upward revision in the pric…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.